Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions

Anna M. Tanasijevic; Anna Revette; Heidi D. Klepin; Amer Zeidan; Danielle Townsley; Courtney D. DiNardo; Marie Sebert; Amy E. DeZern; Richard M. Stone; Emily S. Magnavita; Richard Chen; Mikkael A. Sekeres; Gregory A. Abel

doi:10.1080/10428194.2020.1791854

Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions

Anna M. Tanasijevic, Anna Revette, Heidi D. Klepin, Amer Zeidan, Danielle Townsley, Courtney D. DiNardo, Marie Sebert, Amy E. DeZern, Richard M. Stone, Emily S. Magnavita, Richard Chen, Mikkael A. Sekeres, Gregory A. Abel

Leukemia

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

The anemia of MDS often results in decreased quality of life, which is invoked to justify red cell transfusions; however, there are sparse data regarding the minimum hemoglobin (Hb) at which it is safe to forgo transfusions for patients with no evidence of end-organ damage. This issue is even more important in the COVID-19 era, where decreases in blood donations have stressed the blood supply. In March 2018, using a modified Delphi method, we convened a panel of 13 expert MDS clinicians for three iterative rounds to discuss a minimum safe Hb for this population. While the panel was unable to reach the pre-set consensus of 75% for a specific Hb threshold, there was 100% consensus that it be no greater than 7.5 g/dL. Our data suggest that, given no end-organ effects of anemia, patients with MDS can safely forgo transfusions with a Hb of 7.5 g/dL or higher.

Original language	English (US)
Pages (from-to)	2900-2904
Number of pages	5
Journal	Leukemia and Lymphoma
DOIs	https://doi.org/10.1080/10428194.2020.1791854
State	Published - 2020

Keywords

Myelodysplastic syndromes
hemoglobin threshold
transfusion

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2020.1791854

Cite this

Tanasijevic, A. M., Revette, A., Klepin, H. D., Zeidan, A., Townsley, D., DiNardo, C. D., Sebert, M., DeZern, A. E., Stone, R. M., Magnavita, E. S., Chen, R., Sekeres, M. A., & Abel, G. A. (2020). Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. Leukemia and Lymphoma, 2900-2904. https://doi.org/10.1080/10428194.2020.1791854

@article{549fd1f0a6a845efb98fb5c5bcde9b10,

title = "Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions",

abstract = "The anemia of MDS often results in decreased quality of life, which is invoked to justify red cell transfusions; however, there are sparse data regarding the minimum hemoglobin (Hb) at which it is safe to forgo transfusions for patients with no evidence of end-organ damage. This issue is even more important in the COVID-19 era, where decreases in blood donations have stressed the blood supply. In March 2018, using a modified Delphi method, we convened a panel of 13 expert MDS clinicians for three iterative rounds to discuss a minimum safe Hb for this population. While the panel was unable to reach the pre-set consensus of 75% for a specific Hb threshold, there was 100% consensus that it be no greater than 7.5 g/dL. Our data suggest that, given no end-organ effects of anemia, patients with MDS can safely forgo transfusions with a Hb of 7.5 g/dL or higher.",

keywords = "Myelodysplastic syndromes, hemoglobin threshold, transfusion",

author = "Tanasijevic, {Anna M.} and Anna Revette and Klepin, {Heidi D.} and Amer Zeidan and Danielle Townsley and DiNardo, {Courtney D.} and Marie Sebert and DeZern, {Amy E.} and Stone, {Richard M.} and Magnavita, {Emily S.} and Richard Chen and Sekeres, {Mikkael A.} and Abel, {Gregory A.}",

note = "Funding Information: This work was supported by a grant from the Dresner Foundation Myelodysplastic Syndrome (MDS) Research Fund. Publisher Copyright: {\textcopyright} 2020, {\textcopyright} 2020 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2020",

doi = "10.1080/10428194.2020.1791854",

language = "English (US)",

pages = "2900--2904",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions

AU - Tanasijevic, Anna M.

AU - Revette, Anna

AU - Klepin, Heidi D.

AU - Zeidan, Amer

AU - Townsley, Danielle

AU - DiNardo, Courtney D.

AU - Sebert, Marie

AU - DeZern, Amy E.

AU - Stone, Richard M.

AU - Magnavita, Emily S.

AU - Chen, Richard

AU - Sekeres, Mikkael A.

AU - Abel, Gregory A.

N1 - Funding Information: This work was supported by a grant from the Dresner Foundation Myelodysplastic Syndrome (MDS) Research Fund. Publisher Copyright: © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2020

Y1 - 2020

N2 - The anemia of MDS often results in decreased quality of life, which is invoked to justify red cell transfusions; however, there are sparse data regarding the minimum hemoglobin (Hb) at which it is safe to forgo transfusions for patients with no evidence of end-organ damage. This issue is even more important in the COVID-19 era, where decreases in blood donations have stressed the blood supply. In March 2018, using a modified Delphi method, we convened a panel of 13 expert MDS clinicians for three iterative rounds to discuss a minimum safe Hb for this population. While the panel was unable to reach the pre-set consensus of 75% for a specific Hb threshold, there was 100% consensus that it be no greater than 7.5 g/dL. Our data suggest that, given no end-organ effects of anemia, patients with MDS can safely forgo transfusions with a Hb of 7.5 g/dL or higher.

AB - The anemia of MDS often results in decreased quality of life, which is invoked to justify red cell transfusions; however, there are sparse data regarding the minimum hemoglobin (Hb) at which it is safe to forgo transfusions for patients with no evidence of end-organ damage. This issue is even more important in the COVID-19 era, where decreases in blood donations have stressed the blood supply. In March 2018, using a modified Delphi method, we convened a panel of 13 expert MDS clinicians for three iterative rounds to discuss a minimum safe Hb for this population. While the panel was unable to reach the pre-set consensus of 75% for a specific Hb threshold, there was 100% consensus that it be no greater than 7.5 g/dL. Our data suggest that, given no end-organ effects of anemia, patients with MDS can safely forgo transfusions with a Hb of 7.5 g/dL or higher.

KW - Myelodysplastic syndromes

KW - hemoglobin threshold

KW - transfusion

UR - http://www.scopus.com/inward/record.url?scp=85088149755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088149755&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1791854

DO - 10.1080/10428194.2020.1791854

M3 - Article

C2 - 32667230

AN - SCOPUS:85088149755

SN - 1042-8194

SP - 2900

EP - 2904

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

ER -

Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this